Suppliers / Shenzhen Haibin Pharmaceutical

Shenzhen Haibin Pharmaceutical

China Updated 9 July 2026

Shenzhen Haibin Pharmaceutical is an API manufacturer based in China. It holds 6 active US drug master files and 2 valid CEPs across a filed portfolio of 4 molecules. Its filings concentrate with NCELS (KZ), ARCSA (EC) and INVIMA (CO). Its GMP standing is certified by MFDS (Korea) and EMA.

6
active US DMFs
2
valid CEPs
3
registered plants 1 with an FDA FEI number
7
filings across 3 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Registered plants

Site FDA FEI
Shenzhen City, China Not on file
Shenzhen, China Not on file
China, China 3041598181

What they file, and where

Molecule Regulators Docs
Meropenem US FDA 4
Meropenem Trihydrate EDQM 2
Efinaconazole US FDA 1
Oseltamivir US FDA 1

Also appears on these molecule pages

Filings and GMP by regulator

Regulator Filings GMP certificates
NCELS (KZ) 4 None
ARCSA (EC) 2 None
INVIMA (CO) 1 None
MFDS (Korea) None 2
EMA None 1

Comparing suppliers?

Choose your molecules and target markets. Shenzhen Haibin Pharmaceutical comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates